SPONSOR
National Research Center for Hematology, Russia
Total Trials
2
Recruiting
2
Phases
Phase 3
Conditions studied: Refractory Acute Myeloid LeukemiaEarly Relapses of Acute Myeloid LeukemiaPrimary Mediastinal Lymphoma
National Research Center for Hematology, Russia is a clinical research sponsor with 2 registered studies on ClinicalTrials.gov, of which 2 are actively recruiting participants. Research covers conditions including Refractory Acute Myeloid Leukemia, Early Relapses of Acute Myeloid Leukemia, Primary Mediastinal Lymphoma.
The trial portfolio spans Phase 3 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.
Frequently Asked Questions — National Research Center for Hematology, Russia
How many clinical trials has National Research Center for Hematology, Russia sponsored?
ClinicalMetric currently tracks 2 clinical trials sponsored by National Research Center for Hematology, Russia, of which 2 are actively recruiting participants. These trials cover conditions including Refractory Acute Myeloid Leukemia, Early Relapses of Acute Myeloid Leukemia, Primary Mediastinal Lymphoma. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.
What therapeutic areas does National Research Center for Hematology, Russia research focus on?
National Research Center for Hematology, Russia clinical trials span Refractory Acute Myeloid Leukemia, Early Relapses of Acute Myeloid Leukemia, Primary Mediastinal Lymphoma. The research pipeline includes Phase 3 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.
How do I participate in a National Research Center for Hematology, Russia clinical trial?
To participate in a National Research Center for Hematology, Russia trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all National Research Center for Hematology, Russia trials with current recruitment status updated daily.
Clinical Trials by National Research Center for Hematology, Russia
NCT06418776 Phase 3
Recruiting
IMPACT-AML: Randomized Pragmatic Clinical Trial for Relapsed or Refractory AML
Refractory Acute Myeloid Leukemia
NCT06188676 Phase 3
Recruiting
Multicenter Study of Safety and Efficacy Nivolumab at the Fixed Dose 40 mg (Nivo40) in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed PMBL
Primary Mediastinal Lymphoma
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: September 2026 · Data Methodology